Navigation Links
Reportlinker Adds Global Synthetic Biology Industry
Date:10/4/2010

NEW YORK, Oct. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Synthetic Biology Industry

http://www.reportlinker.com/p0305188/Global-Synthetic-Biology-Industry.html

This report analyzes the Global market for Synthetic Biology in US$ Million by the following three important application areas: Energy & Chemicals, Biotechnology & Pharmaceuticals, and Research & Development. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 51 companies including many key and niche players such as Amyris Biotechnologies, Inc., ATG Biosynthetics GmbH, Blue Heron Biotechnology, Inc., BP Plc, Chromatin Inc., DNA2.0, Draths Corp., febit Synbio GmbH, GENEART AG, GenScript USA, Inc., Gevo, Inc., Joule Biotechnologies, Inc., LC Sciences, LS9, Inc., OPXBIO Inc., Solazyme, Inc., Sloning BioTechnology GmbH, Synthetic Genomics, Inc., and Verdezyne, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

SYNTHETIC BIOLOGY MCP-6581

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Synthetic Biology - An Overview II-1

Current & Future Analysis II-1

Market Scenario II-1

Food and Other Basic Needs' Scarcity to Fuel Synthetic Biology

Market II-2

Food, Water, and Energy Statistics II-2

Future Outlook II-2

Synthetic Biology – An Emerging Discipline II-3

Synthetic Biology - Challenges II-4

Contribution of Synthetic Biology to Biotech II-4

Key developments in the Synthetic Biology Field: II-4

Systems Biology Leading to Advancements in Synthetic Biology II-5

US and Europe - Propelling Research in the Field of Synthetic

Biology II-5

Research in the US II-5

Research in Europe II-6

Scotland – R&D Scenario II-7

State of Synthetic Biology Research In the UK II-7

International Genetically Engineered Machine (IGEM) – A

Platform for Innovations II-8

2. PRODUCT OVERVIEW II-9

Introduction II-9

Historical Background II-9

Synthetic Biology Vis-à-vis Genetic Engineering - A Comparison II-9

Scope of Synthetic Biology in Various Fields II-10

Engineering II-10

Chemistry II-10

Major Enabling Technologies II-10

Sequencing II-10

Fabrication II-11

Modeling II-11

Measurement II-11

Market Potential II-11

Pharmaceutical II-11

Industrial II-11

Agriculture II-11

Life Sciences Research II-11

Renewable Energy II-11

Potential Uses II-12

Biomedicine II-12

Intricate Molecular Devices Utilized for Tissue

Regeneration/Repair II-12

Smart Drugs II-12

Biological Delivery Systems II-12

Vectors for Therapy II-12

Personalized Medicine II-13

Cells with Novel Properties for Betterment of Human Health II-13

In Vivo Synthesis of Small-Molecule Pharmaceuticals II-13

Intricate Natural Products II-13

Expansion of Chemistry of Life II-13

Expanding Genetic Alphabet II-14

Nucleic Acids II-14

Proteins II-14

New Imaging and Targeting Methods II-14

Chemical Industry Sustainability II-14

Eco-friendly Production of Chemicals II-14

Energy and Environment II-15

Bioremediation II-15

Energy Production II-15

Biomaterials and Smart Materials Production II-15

Synthesis II-15

Organization II-15

Socio-Economic Concerns and Risks II-16

Production of Bio-Weapons II-16

Accidental Release II-16

Return on Investment II-16

Dissonance with Other Disciplines II-16

Continuous Evolution II-16

Curtailed Understanding II-16

Unpredictable Ecosystem Effects II-17

Unexpected Transfer of Genes II-17

Aggravating Problems II-17

Lack of Regulatory Framework II-17

Industry Associations II-17

Synthetic Biology Industry Association (SynBIA) II-17

Industry Association of Synthetic Biology (IASB) II-18

Researchers at JCVI Make Novel Advances in Synthetic Genomics II-18

3. PRODUCT INNOVATIONS/INTRODUCTIONS II-20

454 Life Sciences to Introduce GS Junior System and Improve

Genome Sequencer FLX System II-20

DNA2.0 Launches pJexpress II-20

febit Introduces miRBase 14.0-based miRNA Biochip II-20

Codexis Launches CodexTM MicroCyp Plate II-21

GeneWorks Expands Genome Analysis Services II-21

4. RECENT INDUSTRY ACTIVITY II-22

Amyris Brasil Inks Agreements with Acucar Guarani, Bunge and

Cosan Group II-22

Amyris Brasil Inaugurates Demonstration Facility II-22

Amyris Biotechnologies to Acquire Stake in Boa Vista Mill from

São Martinho Group II-22

Synthetic Genomics Inks Agreement with ExxonMobil Research and

Engineering Company II-23

Verdezyne Inks Agreement with Novozymes II-23

Verdezyne Collaborates with Genencor II-23

OneWorld Health, Sanofi-aventis and Amyris Biotechnologies

Enter into Partnership II-24

Amyris Biotechnologies Enters into Partnership with Crystalsev II-24

GENEART Extends Partnership with QIAGEN II-25

LC Sciences and DNAVision Enter into Strategic Marketing Alliance II-25

5. FOCUS ON SELECT PARTICIPANTS IN SYNTHETIC BIOLOGY II-26

AMYRIS BIOTECHNOLOGIES, INC. (US) II-26

ATG Biosynthetics GmbH (Germany) II-26

Blue Heron Biotechnology, Inc. (US) II-26

BP Plc. (UK) II-26

Chromatin Inc. (US) II-27

DNA2.0 (US) II-27

Draths Corp. (US) II-27

febit Synbio GmbH (Germany) II-28

GENEART AG (Germany) II-28

GenScript USA, Inc. (US) II-28

Gevo, Inc. (US) II-28

Joule Biotechnologies, Inc. (US) II-29

LC Sciences (US) II-29

LS9, Inc. (US) II-29

OPXBIO Inc. (US) II-30

Solazyme, Inc. (US) II-30

Sloning BioTechnology GmbH (Germany) II-30

Synthetic Genomics, Inc. (US) II-31

Verdezyne, Inc. (US) II-31

6. GLOBAL MARKET PERSPECTIVE II-32

Table 1: World Recent Past, Current and Future Analysis for

Synthetic Biology by End-Use Sector - Energy & Chemicals,

Biotechnology & Pharmaceuticals, and Research & Development

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-32

Table 2: World 10-Year Perspective for Synthetic Biology by

End-Use Sector - Percentage Breakdown of Dollar Sales for

Energy & Chemicals, Biotechnology & Pharmaceuticals, and

Research & Development Markets for Years 2006, 2009 and 2015

(includes corresponding Graph/Chart) II-33

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 51 (including Divisions/Subsidiaries - 52)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 37

Canada 1

Europe 11

France 1

Germany 5

The United Kingdom 3

Rest of Europe 2

Asia-Pacific (Excluding Japan) 2

Latin America 1

------------------------------------------

To order this report:Biotechnology Industry: Global Synthetic Biology Industry

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Global Soft Tissue Allografts Industry
2. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
3. Reportlinker Adds Shire plc: PharmaVitae Profile
4. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
5. Reportlinker Adds Proteomics - Technologies, Markets and Companies
6. Reportlinker Adds Biotechnology Pharmaceutical Market in US -2013
7. Reportlinker Adds US Vaccines Market
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. Reportlinker Adds Womens Infertility - Pipeline Assessment and Market Forecasts to 2017
10. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
11. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Laurel, NJ (PRWEB) , ... December 06, 2016 ... ... white paper on December 1, 2016 asking the Federal Drug Administration (FDA) to ... the study of OA, OARSI is concerned about the growing population of OA ...
(Date:12/6/2016)... Colorado (PRWEB) , ... December 06, 2016 , ... ... dynamic aqueous plasma technology platforms, announced today that the company has engaged in ... Research and Development Agreement (MRDA) with the CSU Office of the Vice President ...
(Date:12/6/2016)... PHOENIX and SAN DIEGO ... (OTCQB:CELZ) announced the appointment of Santosh Kesari , ... Board. Dr. Kesari will leverage his experience in neurology and ... its adult stem cell for treatment of stroke. The AmnioStem ... amniotic fluid, which has previously shown therapeutic activity in ...
(Date:12/6/2016)... MELBOURNE, Australia , Dec. 6, 2016  The ... Health Informatics Society of Australia (HISA) today announced ... technology startup exchange program between Australia ... city in the world. HISA and ... are initiating a program to create a global health ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/17/2016)... 2016  AIC announces that it has just released a new white paper authored ... scale-out plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):